Merck Settles Patent Infringement Case for Zetia (ezetimibe)
Merck & Co., Inc. and Glenmark Pharmaceuticals Inc., USA and Glenmark Pharmaceuticals, Ltd. have reached an agreement to settle their patent litigation involving Glenmark's challenge to Merck's patent covering ZETIA® (ezetimibe). Specifically, Glenmark challenged Merck's basic compound patent, RE 37,721 (the "721 patent") on numerous grounds.
Under the agreement, Glenmark will be able to launch their product on December 12, 2016 or earlier under certain circumstances, ahead of the April 25, 2017 expiration of Merck's patent exclusivity for ZETIA.
This settlement effectively ends the lawsuit that was scheduled to begin on May 12, involving a challenge by Glenmark which sought to launch a generic version of ZETIA before the April 2017 expiration of the patent exclusivity covering ZETIA.
Most read news
Organizations
Other news from the department politics & laws

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Merck awards its 2017 Grant for Fertility Innovation (GFI) to research projects - Professor Lunenfeld honored with Merck Lifetime Achievement Award

Scientists use fruit peel to turn old batteries into new - Using orange peel to efficiently recover precious metals from battery waste
Millipore Expands BioPharma CRO Services in Europe
Key factor in mitochondrial calcium uptake and bioenergetics identified
Frost & Sullivan: BRIC is not delivering promises of high growth in healthcare markets - The dialogue evolves as it’s no longer about volume, cost and size
QIAGEN Acquires Biosystems Business from Biotage - Transaction adds fundamental assay technology for high-resolution sequence detection and quantification of genetic variations
2,6-Di-tert-butylphenol

Accessing DNA in the cell's powerhouse to treat disease
Seeing the colored light - Bee brains open way for better cameras
